Debenture Agreements in the Biotechnology Industry

80 Contracts & Agreements

Browse by Company

Advaxis, Inc. (1 contract)
ANAVEX LIFE SCIENCES CORP. (3)
Anixa Biosciences Inc (1)
AzurRx BioPharma, Inc. (2)
BIOVIE INC. (1)
BIOXYTRAN, INC (4)
Blue Water Vaccines Inc. (1)
CareDx, Inc. (1)
Cellectar Biosciences, Inc. (1)
Chanticleer Holdings, Inc. (2)
GENEREX BIOTECHNOLOGY CORP (6)
GeoVax Labs, Inc. (1)
GT Biopharma, Inc. (10)
HARBOR DIVERSIFIED, INC. (2)
IMMUNE PHARMACEUTICALS INC (5)
Inspyr Therapeutics, Inc. (8)
MATEON THERAPEUTICS INC (2)
Organicell Regenerative Medicine, Inc. (1)
Propanc Biopharma, Inc. (2)
Protalix BioTherapeutics, Inc. (1)
Q BioMed Inc. (8)
Qrons Inc. (7)
RITTER PHARMACEUTICALS INC (2)
SELLAS Life Sciences Group, Inc. (2)
TG THERAPEUTICS, INC. (1)
Tonix Pharmaceuticals Holding Corp. (2)
Trovagene, Inc. (1)
VACCINEX, INC. (2)

Recent Contracts

Form of 8% Convertible Debenture to be issued by the Company to Alpha Capital Anstalt [Exhibit A to the Securities Purchase Agreement dated February 26, 2024] (RITTER PHARMACEUTICALS INC, Filed With SEC on February 27, 2024)
Debenture, dated January 23, 2024 (Blue Water Vaccines Inc., Filed With SEC on January 29, 2024)
8% Senior Convertible Debenture Due December 22, 2025 (RITTER PHARMACEUTICALS INC, Filed With SEC on December 22, 2022)
Fifth Amendment to $10,000 8% Convertible Debenture, dated October 7, 2021 (Qrons Inc., Filed With SEC on December 1, 2021)
Fourth Amendment to $15,000 8% Convertible Debenture, dated October 7, 2021 (Qrons Inc., Filed With SEC on December 1, 2021)
The Convertible Debenture (Q BioMed Inc., Filed With SEC on October 7, 2021)
Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on June 21, 2021)
Form of Debenture (Q BioMed Inc., Filed With SEC on February 16, 2021)
Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on January 12, 2021)
Form of Debenture (Q BioMed Inc., Filed With SEC on December 29, 2020)
Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on October 29, 2020)
7% Original Issue Discount Senior Convertible Debenture due August 3, 2021 (VACCINEX, INC., Filed With SEC on August 14, 2020)
Form of 7% Original Issue Discount Senior Secured Convertible Debenture due August 3, 2021 (VACCINEX, INC., Filed With SEC on July 31, 2020)
Form of 5% Original Issue Discount Senior Secured Convertible Debenture dated June 26, 2020 (GeoVax Labs, Inc., Filed With SEC on June 26, 2020)
8% Convertible Debenture of Bioxytran, Inc. to Power Up Lending Group LLC in the Principal Amount of $64,900 dated March 18, 2020 (BIOXYTRAN, INC, Filed With SEC on March 26, 2020)
Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on March 6, 2020)
8% Convertible Debenture of Bioxytran, Inc. to Power Up Lending Group LLC in the Principal Amount of $56,600 dated January 18, 2020 (BIOXYTRAN, INC, Filed With SEC on February 26, 2020)
Form of Debenture (Q BioMed Inc., Filed With SEC on December 12, 2019)
Convertible Debenture of Bioxytran, Inc. to Peak One Opportunity Fund, L.P. in the Principal Amount of $120,000 dated October 22, 2019 (BIOXYTRAN, INC, Filed With SEC on November 5, 2019)
8% Convertible Debenture of Bioxytran, Inc. to Peak One Opportunity Fund, L.P. in the Principal Amount of $120,000 dated October 22, 2019 (BIOXYTRAN, INC, Filed With SEC on October 28, 2019)
Form of Debenture (Q BioMed Inc., Filed With SEC on October 15, 2019)
Form of 10% OID Convertible Delayed Draw Debenture (BIOVIE INC., Filed With SEC on September 25, 2019)
The Convertible Debenture (Q BioMed Inc., Filed With SEC on September 6, 2019)
Form of Debenture, issued by the Company to the Bridge Investors (MATEON THERAPEUTICS INC, Filed With SEC on April 18, 2019)
Form of Debenture, issued by the Company to PeakOne (MATEON THERAPEUTICS INC, Filed With SEC on April 18, 2019)
Amendment to 8% Secured Debentures by and between the Company and Debenture Holders (Chanticleer Holdings, Inc., Filed With SEC on April 1, 2019)
Second Amendment to the $10,000 8% Convertible Debenture, dated September 9, 2018 (Qrons Inc., Filed With SEC on March 25, 2019)
First Amendment to $15,000 8% Convertible Debenture, dated September 9, 2018 (Qrons Inc., Filed With SEC on March 25, 2019)
Form of 2018 6% Convertible Debenture Issued by Biotech Products Services And Research, Inc., a Nevada corporation (Organicell Regenerative Medicine, Inc., Filed With SEC on November 1, 2018)
Form of Debenture (IMMUNE PHARMACEUTICALS INC, Filed With SEC on October 10, 2018)
Form of 10% Senior Convertible Debenture (GT Biopharma, Inc., Filed With SEC on September 28, 2018)
Form of Debenture (Q BioMed Inc., Filed With SEC on September 24, 2018)
Form of 10% Senior Convertible Debenture (GT Biopharma, Inc., Filed With SEC on September 7, 2018)
Form of 10% Senior Convertible Debenture (GT Biopharma, Inc., Filed With SEC on August 3, 2018)
Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on July 3, 2018)
Form of Convertible Debenture (IMMUNE PHARMACEUTICALS INC, Filed With SEC on May 14, 2018)
8% Convertible Debenture, dated September 27, 2017, between the Company and CubeSquare LLC (Qrons Inc., Filed With SEC on March 2, 2018)
First Amendment to 8% Convertible Debenture, dated September 28, 2017, between the Company and CubeSquare LLC (Qrons Inc., Filed With SEC on March 2, 2018)
Modification to 12% Senior Secured Original Issue Discount Convertible Debenture, dated November 10, 2017 (AzurRx BioPharma, Inc., Filed With SEC on November 13, 2017)
Form of Senior Convertible Debenture (Inspyr Therapeutics, Inc., Filed With SEC on September 12, 2017)